Synta Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synta Pharmaceuticals

SNTA 0.343

+26.6%

Jul 22 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	12/28/2007 3:21:20 PM
	Read Replies (1) of 112

Checking out slides from Lazard presentation last month, a couple of observations . . . milestones of note: elesclomol interim look for safety and non-futility in 1H08. Enrollment complete and possibly have data analyzed by year end (probably a stretch on the latter). That's the biggie. But also presentation of data on STA-9090 in 2008. Which is supposed to be like Hsp-90 inhibitors of the 17-AAG but chemically distinct from those currently in development, and at least 10 times more potent. P1 is enrolling. Also, expect P2s for elesclomol in other indications to start in 2008. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next